Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters

Citation
Pergolini, I., V. Morales-Oyarvide, M. Mino-Kenudson, K. C. Honselmann, M. W. Rosenbaum, S. Nahar, M. Kem, et al. 2017. “Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival.” PLoS ONE 12 (8): e0182855. doi:10.1371/journal.pone.0182855. http://dx.doi.org/10.1371/journal.pone.0182855.

Published Version
doi:10.1371/journal.pone.0182855

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34491959

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
RESEARCH ARTICLE

Tumor engraftment in patient-derived xenografts of pancreatic ductal adenocarcinoma is associated with adverse clinicopathological features and poor survival

Ilaria Pergolini1,2*, Vicente Morales-Oyarvide1*, Mari Mino-Kenudson3, Kim C. Honselmann1, Matthew W. Rosenbaum3, Sabikun Nahar1, Marina Kem3, Cristina R. Ferrone1, Keith D. Lillemoe1, Nabeel Bardeesy4, David P. Ryan4, Sarah P. Thayer1, Andrew L. Warshaw1, Carlos Fernández-del Castillo1, Andrew S. Liss1*

1 Department of Surgery and the Andrew L. Warshaw, MD Institute for Pancreatic Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 2 Department of Surgery, Università Politecnica delle Marche, Ancona, Italy, 3 Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, 4 Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, United States of America

☯ These authors contributed equally to this work.
¤ Current address: Division of Surgical Oncology and the Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska, United States of America.
* aliss@mgh.harvard.edu

Abstract

Patient-derived xenograft (PDX) tumors are powerful tools to study cancer biology. However, the ability of PDX tumors to model the biological and histological diversity of pancreatic ductal adenocarcinoma (PDAC) is not well known. In this study, we subcutaneously implanted 133 primary and metastatic PDAC tumors into immunodeficient mice. Fifty-seven tumors were successfully engrafted and even after extensive passaging, the histology of poorly-, moderately-, and well-differentiated tumors was maintained in the PDX models. Moreover, the fibroblast and collagen contents in the stroma of patient tumors were recapitulated in the corresponding PDX models. Analysis of the clinicopathological features of patients revealed xenograft tumor engraftment was associated with lymphovascular invasion (P = 0.001) and worse recurrence-free (median, 7 vs. 16 months, log-rank P = 0.047) and overall survival (median, 13 vs. 21 months, log-rank P = 0.038). Among successful engraftments, median time of growth required for reimplantation into new mice was 151 days. Reflective of the inherent biological diversity between PDX tumors with rapid (<151 days) and slow growth, differences in their growth were maintained during extensive passaging. Rapid growth was additionally associated with lymph node metastasis (P = 0.022). The association of lymphovascular invasion and lymph node metastasis with PDX formation and rapid growth may reflect an underlying biological mechanism that allows these tumors to adapt and grow in a new environment. While the ability of PDX tumors to mimic the cellular and non-cellular features of the parental tumor stroma provides a valuable model to study the interaction of PDAC cells with the tumor microenvironment, the association of
successful engraftment with adverse clinicopathological features suggests PDX models over represent more aggressive forms of this disease.

Introduction
Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic cancer, with more than 53,000 cases diagnosed per year in the United States. Only 8% of these patients survive beyond five years, making PDAC the fourth leading cause of cancer-related deaths [1]. The ineffectiveness of treatments and the scant improvement of survival outcomes may be ascribed to the fact that PDAC has historically been modeled as a single disease entity. By contrast, recent advances in genomics have revealed the heterogeneity of this disease [2–4]. Although activating mutations in \textit{KRAS} occur in ~90% of PDAC, there are few additional genes (such as \textit{TP53} and \textit{SMAD4}) commonly mutated or inactivated in pancreatic cancer [5]. Contributing to the challenges associated with treating PDAC is a highly desmoplastic stroma that promotes the aggressive local growth of the tumor and the intrinsic chemo-resistance of the cancer cells [6–9]. Thus, modeling the tumor microenvironment and its crosstalk with the cancer cells is particularly important in developing new therapies for PDAC.

Several \textit{in vitro} and \textit{in vivo} preclinical models are available to study the biology of cancer, including cell lines and xenograft tumors derived from them, genetically-engineered mouse models, organoids, and patient-derived xenograft (PDX) tumor models [10,11]. Among these, PDX tumors have the advantage of mimicking the genetic complexity of human PDAC in a platform that has the potential to recapitulate many of the features of the tumor microenvironment. Moreover, a model that faithfully reflects the original tumor biology may predict clinical outcomes and allow for the development of personalized targeted therapies [12–15]. However, the growth of PDX tumors from pancreatic cancer is variable and the determinants of their growth are unknown [16–19].

Understanding the dynamic behind xenograft tumor formation, the features that affect the success of tumor engraftment, and the prognostic implications could be an important key for new perspectives in the knowledge of pancreatic cancer. The aims of our study were to identify clinical and pathological factors associated with successful tumor engraftment and xenograft growth rate, and to evaluate whether tumor engraftment and xenograft rate of growth were prognostic of patient outcomes. We also analyzed PDX tumors to assess the ability of these models to reproduce the histological features of the original pancreatic tumors.

Materials and methods
Patient population and tumor samples
All study participants provided IRB-approved informed consent for their medical records and tissue samples to be used in this study. Patient clinical data was entered into a de-identified clinical database allowing for the anonymous analysis of demographic, clinical and pathological variables. We collected fresh tumor samples from 133 patients with histologically-confirmed stages I-IV PDAC who underwent surgery for curative intent, diagnostic laparoscopy, or palliation of symptoms at the Massachusetts General Hospital between April, 2009 and July, 2012.

Xenograft tumors
Patient tumor samples were mechanically minced into small fragments (1–2 mm³) and either implanted into mice or cryopreserved in freezing media (10% DMSO, 20% FBS, 70% DMEM/
Ham’s F-12 50/50 supplemented with 1% PS) for future implantation. Cryopreserved tumors were rapidly thawed in a 37°C water bath and washed twice with PBS prior to implantation. For tumor implantation, 6–8 week-old nu/j mice (Jackson Laboratory) were anesthetized with Isoflurane and a small incision made on the dorsal flank. Approximately 70–100 mg of tumor tissue coated in 50–100 μl of Matrigel (Corning, 354248) was subcutaneously implanted into the flank of each mouse and the incision was closed with a single suture (4–0 Coated Vicryl, Ethicon). Mice were administered buprenorphine as needed as an analgesic. Patient tumors were implanted in a median number of 4 mice (range 1–5). In 10.5% of cases the tumor tissue was enough for only one mouse. Mice were monitored weekly for tumor growth. Mice that lacked a palpable tumor after 6 months were removed from the study and the patient tumors were categorized as no engraftment. Successful tumor engraftment was defined as tumors that grew large enough (1 cm) to be reimplanted into new mice. Mice with tumors < 1 cm after 180 days were retained in the study until tumors reached sufficient size for reimplantation. Tumors implanted in mice that were removed from the study due to health reasons before the tumor reached an appropriate size for reimplantation were categorized as no engraftment. For tumors that successfully formed xenografts, we recorded the time of growth between initial implantation and reimplantation into new mice. The presence of pancreatic adenocarcinoma in xenograft tumors was confirmed by histological analysis of hematoxylin and eosin (H&E) stained sections by pathologists with a special interest in pancreatic cancer (M.M.K. and M.W.R). Maximum tumor size in this study did not exceed 1.5 cm. Mice were euthanized by CO₂ asphyxiation in accordance to the guidelines set forth in the American Veterinary Medical Association (AVMA) Guidelines for the Euthanasia of Animals.

Immunohistochemistry

Representative sections of primary human tumors were stained with a 1:50 dilution of a goat polyclonal antibody specific to SMAD4 (sc-1909, Santa Cruz Biotechnology, Dallas, TX, USA) using the Bond RX IHC staining platform (Leica Biosystems, Buffalo Grove, IL, USA) with BOND Epitope Retrieval Solution 2 (Leica Biosystems, AR9640). The staining of SMAD4 was scored by a pathologist and SMAD4 expression was considered preserved (positive) when detected in the nucleus and/or cytoplasm of PDAC cells. Staining of stromal cells in each tumor section was used as an internal positive control. For analysis of cancer-associated fibroblasts, deparaffinized sections of patient and PDX tumors were stained with a 1:200 dilution of a rabbit polyclonal antibody specific to alpha smooth muscle actin (ab5694, Abcam, Cambridge, MA, USA) as described previously [20]. The collagen content of tumors was visualized by picrosirius red staining (Picro Sirius Red Stain Kit, Abcam, Cambridge, MA, USA).

Genetic analysis of patient tumors

DNA extracted from formalin-fixed paraffin-embedded tumor samples from 20 patients was analyzed for somatic mutations using SNaPshot multiplex assays (Applied Biosystems) [21]. Common to these assays were the tests for variants in loci found in APC, BRAF, CTNNB1, EGFR, KIT, KRAS, NOTCH1, NRAS, PI3KA, PTEN, and TP53. On average, approximately 5% mutant allele is sufficient for detection in these assays. Only mutations in KRAS and TP53 were detected in our series.

Outcome measures

The primary outcome measures of this study were successful tumor engraftment and xenograft rate of growth. We also evaluated whether tumor engraftment and xenograft growth rate were associated with patient recurrence-free survival (RFS) and overall survival (OS). RFS was
defined as time between surgery and evidence of disease recurrence or death from any cause; analyses of RFS were restricted to patients with resectable primary tumors and no evidence of metastatic disease (n = 112). OS was defined as time between surgery and death from any cause; analyses of OS were performed in the entire study population. Follow-up continued through February, 2017.

Statistical analysis

We evaluated the associations of clinical and pathological features with tumor engraftment and xenograft rate of growth using univariate analyses. Analyses of categorical data were performed using chi-square or Fisher exact tests, where appropriate; continuous data were analyzed with Mann-Whitney U test. Associations of tumor engraftment and xenograft growth rate with patient survival were analyzed using log-rank tests and multivariable-adjusted Cox proportional hazards regression adjusting for potential confounders. Kaplan-Meier survival curves, median survival time, and two- and five-year survival rates were also presented. Cox regression models adjusted for patient age and sex, receipt of neoadjuvant and adjuvant therapy, American Joint Committee on Cancer (7th edition) clinical stage, tumor differentiation grade, presence of lymphovascular invasion, surgical margins, and tumor location. Statistical significance was set at $P < 0.05$ and all hypothesis tests were two-sided. Statistical analyses were conducted using SAS software (version 9.4; SAS Institute, Cary, NC).

Results

Primary or metastatic tumor samples were collected from 133 patients with histologically-confirmed diagnosis of PDAC. The baseline characteristics of patients in our study are presented in Tables 1 and 2. The median age of the patients in our study was 68 (range 35–93). Fifty-seven (43%) tumors implanted into immunodeficient mice were successfully engrafted, while 76 (57%) failed to do so. A number of studies have reported different methods of cryopreserving tumors for future growth as xenograft tumors [22,23]. In our study, there was no significant difference in the engraftment rate between freshly implanted (n = 24) and cryopreserved (n = 109) tumors (50% vs 41%, $P = 0.498$).

Histological analysis of the xenograft tumors revealed that the grade of differentiation of the human tumors was retained in each of the corresponding xenografts. Moreover, the histology of poorly-, moderately-, and well-differentiated tumors was retained through at least 10 generations in mice (Fig 1A). Characteristic of the stroma of PDAC tumors is the presence of cancer associated fibroblasts and abundance of collagen. The corresponding xenograft tumors contain $\alpha$-smooth muscle actin-expressing fibroblasts similarly to patient tumors (Fig 1B). Furthermore, picrosirius red staining revealed that collagen content of xenograft tumors was largely composed of either organized or disorganized fibers and these collagen subtypes were similarly found within the malignant epithelium of the corresponding patient tumor (Fig 1B). Collectively, these results demonstrate that patient-derived xenograft models of PDAC retain the histological and microenvironmental characteristics of the original tumor.

Clinical and genetic characteristics, pathological features, and tumor engraftment status

To gain insight into the factors that determine tumor engraftment, we evaluated the demographic, clinical, and pathological characteristics of patients based on tumor engraftment status (Tables 1 and 2). We found no significant associations between demographic or clinical features and tumor engraftment. Neoadjuvant chemotherapy has become increasingly common in patients with PDAC and is associated with increased fibrosis and a reduction in viable
Table 1. Baseline demographic and clinical characteristics of 133 patients with resected pancreatic ductal adenocarcinoma by tumor engraftment status.

| Characteristic                              | Overall | Tumor engraftment | P value |
|---------------------------------------------|---------|-------------------|---------|
|                                             | Yes     | No                |         |
| No. Patients                                | 133     | 57 (43%)          | 76 (57%)|         |
| Men, n (%)                                  | 70 (53%)| 34 (60%)          | 36 (47%)| 0.160   |
| Age, median (IQR)                           | 68 (18) | 66 (16)           | 70 (18.5)| 0.730   |
| Serum CA19-9, median (IQR)                  | 128 (376.6) | 118 (347.0) | 128.5 (436.5) | 0.916 |
| Body mass index, median (IQR)               | 25.9 (6.0) | 26.8 (6.3) | 25.2 (6.0) | 0.390   |
| Diabetes, n (%)                             | 101 (76%)| 41 (72%)          | 60 (79%)| 0.345   |
| New-onset or worsening diabetes, n (%)*     | 11 (34%)| 6 (37%)           | 5 (31%) | 0.809   |
| Neoadjuvant therapy, n (%)                  | 91 (68%)| 42 (74%)          | 49 (64%)| 0.258   |
| Resection, n (%)                            | 17 (13%)| 9 (16%)           | 8 (11%) | 0.368   |
| Metastatic disease, n (%)                   | 112 (84%)| 45 (79%)          | 67 (88%)| 0.149   |
| Type of resection, n (%)                    | 91 (68%)| 34 (59%)          | 57 (75%)| 0.131   |
| Whipple                                     | 4 (3%)  | 1 (2%)            | 3 (4%)  |       |
| Middle                                      | 20 (15%)| 13 (23%)          | 7 (9%)  |       |
| Distal                                      | 1 (1%)  | -                 | 1 (1%)  |       |
| No resection                                | 17 (13%)| 9 (16%)           | 8 (11%) |       |
| Adjuvant therapy, n (%)**                   | 30 (27%)| 10 (22%)          | 20 (30%)| 0.421   |
| Yes                                         | 79 (70%)| 33 (73%)          | 46 (69%)|       |
| Unknown                                     | 3 (3%)  | 2 (5%)            | 1 (1%)  |       |
| Recurrence, n (%)**                         | 28 (25%)| 9 (20%)           | 19 (28%)| 0.317   |
| Yes                                         | 84 (75%)| 36 (80%)          | 48 (72%)|       |
| Site of recurrence, n (%)***                | 21 (25%)| 9 (25%)           | 12 (25%)| 0.488   |
| Locoregional                                 | 54 (64%)| 24 (67%)          | 30 (63%)|       |
| Distant                                     | 8 (10%) | 2 (5%)            | 6 (12%) |       |
| Both locoregional and distant               | 1 (1%)  | 1 (3%)            | -       |       |

Abbreviations: IQR, interquartile range.
*Among patients with diabetes mellitus (n = 32).
** Among patients undergoing resection with curative intent and absence of metastatic disease (n = 112).
*** Among patients with evidence of recurrence following resection with curative intent (n = 84).

https://doi.org/10.1371/journal.pone.0182855.t001
Table 2. Pathologic characteristics of 133 patients with resected pancreatic ductal adenocarcinoma by tumor engraftment status.

|                          | Overall | Tumor engraftment |      |      |      |
|--------------------------|---------|-------------------|------|------|------|
|                          |         | Yes | No |      |      |
| No. Patients             | 133 | 57 (43%) | 76 (57%) |      |      |
| Tumor differentiation grade, n (%) |       |      |      |      |      |
| Well differentiated      | 7 (5%) | 3 (5%) | 4 (5%) | 0.846 |      |
| Moderately differentiated | 65 (49%) | 26 (46%) | 39 (52%) |      |      |
| Poorly differentiated    | 53 (40%) | 24 (42%) | 29 (38%) |      |      |
| Unknown                  | 8 (6%) | 4 (7%) | 4 (5%) |      |      |
| AJCC 7th ed. stage, n (%) |       |      |      |      |      |
| IA                       | 1 (1%) | 1 (2%) | - | 0.333 |      |
| IB                       | 6 (4%) | 2 (3%) | 4 (5%) |      |      |
| IIA                      | 17 (13%) | 5 (9%) | 12 (16%) |      |      |
| IIB                      | 88 (66%) | 37 (65%) | 51 (67%) |      |      |
| III                      | - | - | - |      |      |
| IV                       | 21 (16%) | 12 (21%) | 9 (12%) |      |      |
| AJCC 7th ed. pT, n (%)*  |       |      |      |      |      |
| pT1                      | 2 (2%) | 1 (2%) | 1 (2%) | 0.928 |      |
| pT2                      | 11 (10%) | 4 (9%) | 7 (10%) |      |      |
| pT3                      | 99 (88%) | 40 (89%) | 59 (88%) |      |      |
| pT4                      | - | - | - |      |      |
| AJCC 7th ed. pN, n (%)*  |       |      |      |      |      |
| pN0                      | 24 (21%) | 8 (18%) | 16 (24%) | 0.440 |      |
| pN1                      | 88 (79%) | 37 (82%) | 51 (76%) |      |      |
| Tumor location, n (%)    |       |      |      |      |      |
| Body/Tail                | 30 (23%) | 18 (32%) | 12 (16%) | 0.031 |      |
| Head/Uncinate            | 103 (77%) | 39 (68%) | 64 (84%) |      |      |
| Size cm, median (IQR)*   | 3.0 (1.5) | 3.5 (1.7) | 2.8 (1.6) | 0.051 |      |
| Lymphovascular invasion, n (%) |       |      |      |      |      |
| Absent                   | 40 (30%) | 8 (14%) | 32 (42%) | 0.001 |      |
| Present                  | 81 (61%) | 43 (75%) | 38 (50%) |      |      |
| Unknown                  | 12 (9%) | 6 (11%) | 6 (8%) |      |      |
| Perineural invasion, n (%) |       |      |      |      |      |
| Absent                   | 6 (4%) | 2 (3%) | 4 (5%) | 0.681 |      |
| Present                  | 110 (83%) | 46 (81%) | 64 (84%) |      |      |
| Unknown                  | 17 (13%) | 9 (16%) | 8 (11%) |      |      |
| Surgical margins, n (%)* |       |      |      |      |      |
| R0                       | 98 (87%) | 41 (91%) | 57 (85%) | 0.532 |      |
| R1                       | 13 (12%) | 4 (9%) | 9 (13%) |      |      |
| R2                       | 1 (1%) | - | 1 (2%) |      |      |
| SMAD4, n (%)**           |       |      |      |      |      |
| Retained                 | 40 (62%) | 20 (69%) | 20 (57%) | 0.331 |      |
| Lost                     | 24 (38%) | 9 (31%) | 15 (43%) |      |      |

Abbreviations: IQR, interquartile range.

*Among patients undergoing resection with curative intent and absence of metastatic disease (n = 112).

**Among tumors with available SMAD4 immunohistochemistry (n = 64).

https://doi.org/10.1371/journal.pone.0182855.t002
cancer cells, which could influence the ability of a tumor to successfully establish a xenograft [24]. Notably, 42 (32%) patients in our series received neoadjuvant chemotherapy and this did not adversely affect tumor engraftment (Table 1).

Analysis of pathological features of patient tumors demonstrated that lymphovascular invasion and location of the primary tumor within the pancreas were significantly associated with tumor engraftment. Tumors with successful engraftment had higher frequency of lymphovascular invasion (43/57, 75%) compared to tumors that did not form xenografts (38/76, 50%; \( P = 0.001 \)). Among patients whose tumors successfully engrafted, primary tumors were located...
in the body and tail of the pancreas in 32% (18/57) of cases; in contrast, only 16% (12/76) of primary tumors that did not engraft were located in the pancreatic body and tail ($P = 0.031$). Features such as tumor grade, nodal metastases, or type of implanted tumor tissue (i.e., primary vs. metastatic) were not significantly associated with engraftment status.

To evaluate whether common molecular alterations found in PDAC are associated with tumor engraftment, we performed genetic analysis of $KRAS$ and $TP53$, and immunohistochemistry for SMAD4. Genetic analysis of engrafted and non-engrafted tumors revealed 18/20 (90%) tumors contained activating mutations in codon 12 or 61 of $KRAS$, while hot spot mutations in $TP53$ were identified in three (15%) tumors (Fig 2A). However, there was no association between these mutations and the success of tumor engraftment. SMAD4 is frequently inactivated in PDAC through both genetic and epigenetic mechanisms [25]. Therefore, we employed immunohistochemistry to evaluate the expression of SMAD4 in 64 patient tumors, 45% of which were successfully engrafted (Fig 2B). The expression of SMAD4 was lost in 38% of tumors, and there was no significant difference in the loss of SMAD4 expression between engrafted and non-engrafted tumors (31% vs 43%, $P = 0.331$, Fig 2C). Taken together, these results suggest that alterations in these core PDAC pathways are not predictive of tumor engraftment.

Clinical characteristics, pathological features, and xenograft growth rate

Among successful engraftments, the median time of growth required for reimplantation into new mice was 151 days (range 39–346 days; Fig 3A). Xenograft tumors that were reimplanted in less than 151 days were defined as having a rapid growth rate. Analysis of representative rapid and slow ($\geq$ 151 days) xenograft tumor lines revealed that the relative differences in the growth rate of these tumors was maintained for at least 10 generations (Fig 3B). Since these differences in the time to tumor engraftment may be related to the inherent characteristics of the
tumor biology, we performed a comparison of the clinical (Table 3) and pathological (Table 4) features between tumors with rapid and slow growth. Rapid growth was significantly associated with patients of male gender ($P = 0.020$), primary tumors located in the head of the pancreas ($P = 0.029$), and lymph node metastases ($P = 0.022$). Collectively, our results suggest that both tumor engraftment and xenograft growth rate are associated with adverse pathological features (e.g. lymphovascular for tumor engraftment and lymph node metastases for xenograft growth rate).

**Tumor engraftment, rate of growth, and survival outcomes**

To determine the prognostic value of tumor engraftment, we analyzed the relationship between patient survival outcomes and PDX formation and growth rate. Overall, 30 (22.6%)
patients of our cohort were alive at the end of follow-up period, and among them the median follow up time was 45 months. In patients who underwent resection with curative intent without evidence of metastatic disease, the median, 2-year, and 5-year RFS was 10 months (95% CI

Table 3. Baseline demographic and clinical characteristics of 57 patients with patient-derived PDAC xenografts based on xenograft growth rate.

|                           | Overall | Rapid | Slow | P value |
|---------------------------|---------|-------|------|---------|
| No. patients              | 57      | 28 (49%) | 29 (51%) |         |
| Men, n (%)                | 34 (60%) | 21 (75%) | 13 (45%) | 0.020   |
| Age, median (IQR)         | 66 (16.0) | 66 (11.5) | 71 (24) | 0.193   |
| Serum CA19-9, median (IQR)| 118 (347.0) | 145 (376.5) | 94 (195.0) | 0.429   |
| Body mass index, median (IQR) | 26.8 (6.3) | 27.3 (7.9) | 26.3 (5.3) | 0.334   |
| Diabetes, n (%)           |         |       |      |         |
| No                        | 41 (72%) | 20 (71%) | 21 (72%) | 0.934   |
| Yes                       | 16 (28%) | 8 (29%) | 8 (28%) |         |
| New-onset or worsening diabetes, n (%)* |         |       |      |         |
| No                        | 6 (37%) | 2 (25%) | 4 (50%) | 0.608   |
| Yes                       | 10 (63%) | 6 (75%) | 4 (50%) |         |
| Neoadjuvant therapy, n (%)|         |       |      |         |
| No                        | 42 (74%) | 20 (71%) | 22 (76%) | 0.704   |
| Yes                       | 15 (26%) | 8 (29%) | 7 (24%) |         |
| Resection, n (%)          |         |       |      |         |
| No                        | 9 (16%) | 4 (14%) | 5 (17%) | 1.00    |
| Yes                       | 48 (84%) | 24 (86%) | 24 (83%) |         |
| Metastatic disease, n (%) |         |       |      |         |
| No                        | 45 (79%) | 23 (82%) | 22 (76%) | 0.561   |
| Yes                       | 12 (21%) | 5 (18%) | 7 (24%) |         |
| Type of resection, n (%)  |         |       |      |         |
| Whipple                   | 34 (59%) | 20 (72%) | 14 (48%) | 0.253   |
| Middle                    | 1 (2%) | - | 1 (4%) |         |
| Distal                    | 13 (23%) | 4 (14%) | 9 (31%) |         |
| Total                     | - | - | - |         |
| No resection              | 9 (16%) | 4 (14%) | 5 (17%) |         |
| Adjuvant therapy, n (%)** |         |       |      |         |
| No                        | 10 (22%) | 3 (13%) | 7 (32%) | 0.281   |
| Yes                       | 33 (73%) | 18 (78%) | 15 (68%) |         |
| Unknown                   | 2 (5%) | 2 (9%) | - |         |
| Recurrence, n (%)**       |         |       |      |         |
| No                        | 9 (20%) | 3 (13%) | 6 (27%) | 0.284   |
| Yes                       | 36 (80%) | 20 (87%) | 16 (73%) |         |
| Site of recurrence, n (%)*** |         |       |      |         |
| Locoregional              | 9 (25%) | 5 (25%) | 4 (25%) | 0.412   |
| Distant                   | 24 (67%) | 13 (65%) | 11 (69%) |         |
| Both locoregional and distant | 2 (5%) | 2 (10%) | - |         |
| Unknown                   | 1 (3%) | - | 1 (6%) |         |

Abbreviations: IQR, interquartile range.

*Among patients with diabetes mellitus (n = 16).
** Among patients undergoing resection with curative intent and absence of metastatic disease (n = 45).
*** Among patients with evidence of recurrence following resection with curative intent (n = 36).

https://doi.org/10.1371/journal.pone.0182855.t003
7–15), 25.3%, and 12.7%, respectively. In the entire study population, the median, 2-year, and 5-year OS was 16 months (95% CI 13–19), 38.0%, and 14.7%, respectively.

### Table 4. Baseline pathological characteristics of 57 patients with patient-derived PDAC xenografts based on xenograft growth rate.

|                     | Overall | Rapid | Slow | P value |
|---------------------|---------|-------|------|---------|
| No. patients        | 57      | 28 (49%) | 29 (51%) |
| Tumor differentiation grade, n (%) |         |       |      |         |
| Well differentiated  | 3 (5%)  | 1 (4%) | 2 (7%) | 0.728 |
| Moderately differentiated | 26 (46%) | 14 (50%) | 12 (41%) |
| Poorly differentiated | 24 (42%) | 11 (39%) | 13 (45%) |
| Unknown             | 4 (7%)  | 2 (7%) | 2 (7%) |
| AJCC 7th ed. stage, n (%) |         |       |      |         |
| IA                  | 1 (2%)  | -     | 1 (3.5%) | 0.106 |
| IB                  | 2 (3%)  | 1 (3%) | 1 (3.5%) |
| II A                | 5 (9%)  | -     | 5 (17%) |
| II B                | 37 (65%) | 22 (79%) | 15 (52%) |
| III                 | -       | -     | -     |
| IV                  | 12 (21%) | 5 (18%) | 7 (24%) |
| AJCC 7th ed. pT, n (%)* |         |       |      |         |
| pT1                 | 1 (2%)  | -     | 1 (4%) | 0.304 |
| pT2                 | 4 (9%)  | 1 (4%) | 3 (14%) |
| pT3                 | 40 (89%) | 22 (96%) | 18 (82%) |
| pT4                 | -       | -     | -     |
| AJCC 7th ed. pN, n (%)* |         |       |      |         |
| pN0                 | 8 (18%) | 1 (4%) | 7 (32%) | 0.022 |
| pN1                 | 37 (82%) | 22 (96%) | 15 (68%) |
| Tumor location, n (%) |         |       |      |         |
| Body/Tail           | 18 (32%) | 5 (18%) | 13 (45%) | 0.029 |
| Head/Uncinate       | 39 (68%) | 23 (82%) | 16 (55%) |
| Size cm, median (IQR)* |       |       |      |         |
| Lymphovascular invasion, n (%) |         |       |      |         |
| Absent              | 8 (14%) | 2 (7%) | 6 (21%) | 0.140 |
| Present             | 43 (75%) | 24 (86%) | 19 (65%) |
| Unknown             | 6 (11%) | 2 (7%) | 4 (14%) |
| Perineural invasion, n (%) |         |       |      |         |
| Absent              | 2 (3%)  | -     | 2 (7%) | 0.489 |
| Present             | 46 (81%) | 24 (86%) | 22 (76%) |
| Unknown             | 9 (16%) | 4 (14%) | 5 (17%) |
| Surgical margins, n (%)* |         |       |      |         |
| R0                  | 41 (91%) | 22 (96%) | 19 (66%) | 0.346 |
| R1                  | 4 (9%)  | 1 (4%) | 3 (14%) |
| R2                  | -       | -     | -     |
| SMAD4, n (%)**      |         |       |      |         |
| Retained            | 20 (69%) | 12 (67%) | 8 (73%) | 1.000 |
| Lost                | 9 (31%) | 6 (33%) | 3 (27%) |

Abbreviations: IQR, interquartile range.
*Among patients undergoing resection with curative intent and absence of metastatic disease (n = 45).
**Among tumors with available SMAD4 immunohistochemistry (n = 29).

https://doi.org/10.1371/journal.pone.0182855.t004
Patients with tumors that successfully engrafted had significantly shorter RFS (median, 7 vs. 16 months, log-rank \( P = 0.047; \) Fig 4A) and OS (median, 13 vs. 21 months, log-rank \( P = 0.038; \) Fig 4B) compared to patients with tumors that failed to engraft. Moreover, the multivariable-adjusted survival analyses revealed tumor engraftment as an independent predictor of worse RFS (HR 2.05, 95% CI 1.20–3.50, \( P = 0.009 \)) (Table 5). Survival analyses based on xenograft growth rate did not show significant associations with patient survival outcomes, although analyses were limited by sample size (Table 5, Fig 4C and 4D). Patients with rapidly-growing xenografts had shorter RFS (median, 6 vs. 10 months, log-rank \( P = 0.189 \)) and OS (median, 8 vs. 14, log-rank \( P = 0.328 \)) than those with slow-growing xenografts, although these differences were not statistically significant.

**Discussion**

The genetic heterogeneity of PDAC and the intense desmoplastic reaction of the tumor stroma have made improvements in survival outcomes difficult to achieve. Preclinical models that
closely recapitulate the complexity of human pancreatic cancer are indispensable to study the biology of this disease and assess novel therapeutic agents. In this setting, PDX tumor models of PDAC allow for the faithful propagation of the human neoplastic cells. We showed that the histological architecture of the original tumors is maintained in the PDX models for different grades of differentiation, even after extensive passages. Moreover, although the non-malignant stroma of the human tumor is replaced with cells from the host mouse, these components seem to mimic several features of the original tumor stroma, including cancer-associated fibroblasts (CAFs) and tumor vasculature [26–28]. In PDAC, the CAFs are largely responsible for the production of the extracellular matrix found in the tumor stroma, and the production of collagen by CAFs is mediated by their close association with PDAC cells [29,30]. Despite the replacement of human CAFs by murine fibroblasts, we demonstrated that the collagen structures found in PDX models of PDAC closely resemble those found in the original tumor. Therefore, PDX tumors provide a system to investigate the cellular and non-cellular components of the stroma and their interactions with PDAC cells.

The pathological factors associated with PDX formation have been described for a variety of cancers [31,32]. However, their identification in PDAC has largely remained elusive, with a single study correlating tumor size (> 3.5 cm) with successful xenograft generation [16,18,19]. In our series, we identified lymphovascular invasion and lymph node metastasis as potential determinants for PDX formation and rapid growth, respectively. An important role for lymphovascular invasion is highlighted by the fact that only 14% of tumors without lymphovascular invasion successfully engrafted. These results suggest that engraftment may reflect an underlying biological mechanism that allows these tumors to adapt and grow in a new environment. Interestingly, previous studies employing NOD/SCID mice have failed to make similar correlations with these pathological features and PDAC engraftment and growth [16–18]. While the more immuno-compromised background of these mice likely allows for more efficient tumor engraftment, it is possible that the reduced selective pressure of NOD/SCID mice masks the inherent biological differences of patient tumors.

### Table 5. Recurrence-free and overall survival by tumor engraftment and xenograft growth rate.

|                      | Recurrence-Free Survival | Overall Survival |
|----------------------|--------------------------|-------------------|
|                      | No. patients | Median (Months) | 2-year | 5-year | HR* (95% CI) | P    |
| Tumor engraftment    |              |                |        |        |               |      |
| No engraftment       | 67           | 16.0           | 30.3%  | 15.2%  | 1.00 (reference) |  |
| Engraftment          | 45           | 7.0            | 16.9%  | 8.5%   | 2.05 (1.20–3.50) | 0.009 |
| Xenograft growth rate|              |                |        |        |               |      |
| Slow growth          | 22           | 10.0           | 23.5%  | 0.0%   | 1.00 (reference) |  |
| Rapid growth         | 23           | 6.0            | 10.5%  | 10.5%  | 2.37 (0.90–6.25) | 0.082 |

**Recurrence-Free Survival**

|                      | No. patients | Median (Months) | 2-year | 5-year | HR* (95% CI) |
|----------------------|--------------|-----------------|--------|--------|--------------|
| Tumor engraftment    |              |                |        |        |              |
| No engraftment       | 76           | 21.0           | 48.7%  | 16.5%  | 1.00 (reference) |
| Engraftment          | 57           | 13.0           | 24.3%  | 11.2%  | 1.44 (0.90–2.31) |

**Overall Survival**

|                      | No. patients | Median (Months) | 2-year | 5-year | HR* (95% CI) |
|----------------------|--------------|-----------------|--------|--------|--------------|
| Tumor engraftment    |              |                |        |        |              |
| No engraftment       | 76           | 21.0           | 48.7%  | 16.5%  | 1.00 (reference) |
| Engraftment          | 57           | 13.0           | 24.3%  | 11.2%  | 1.44 (0.90–2.31) |

Abbreviations: HR, hazard ratio.

*Cox proportional hazards regression adjusting for patient age, sex, neoadjuvant therapy, adjuvant therapy, American Joint Committee on Cancer stage, tumor location, tumor grade of differentiation, lymphovascular invasion, and resection margins.

https://doi.org/10.1371/journal.pone.0182855.t005

Pancreatic cancer xenograft tumor models and patient outcomes
The association of molecular alterations with PDAC PDX formation has been controversial. The focus of this analysis has been on the loss of SMAD4 expression, which has been implicated in metastatic spread of PDAC [33]. Previously, Garrido-Laguna et al. found that engrafted tumors were more frequently associated with SMAD4 inactivation [17]. In contrast, in a study by Jun et al. there was no association between loss of SMAD4 and success of tumor engraftment [16]. Similarly, our analysis of SMAD4 expression in patient tumors did not find any correlation with the success or timing of tumor engraftment. Moreover, our study and others have demonstrated that successfully and unsuccessfully engrafted tumors exhibit a similar distribution of KRAS mutations and comparable expression or mutation of TP53. Collectively, these results suggest that that single genetic alterations may not be determinant of tumor engraftment, allowing PDX models of PDAC to recapitulate the broad genetic diversity of patient tumors.

As seen in PDX models of other cancers, successful engraftment of PDAC tumors correlates with shorter recurrence-free and overall survival. In the present study, tumors successfully engrafted in mice showed significantly poorer overall survival and xenograft formation was an independent predictor of poor survival. Similarly, Garrido-Laguna et al. showed that patients whose pancreatic tumors failed to engraft had an 81% reduced risk of death, and Thomas et al. demonstrated that patients whose tumors successfully engrafted experienced recurrence significantly earlier than those whose did not grow [17,18]. Despite the shorter survival of patients with PDAC that form PDX tumors, most tumors are established in mice 4–5 months before recurrence in patients undergoing surgical resection. In our cohort of patients with recurrent disease, xenograft tumors developed a median of 166 days before diagnosis of recurrence. Similarly, Thomas et al. detected first palpable signs of tumor formation a median of 134.5 days before radiographic recurrence identification [18]. Given the limited number of therapeutic options and the variable rate of successful growth, the systematic use of PDX tumors for real-time chemo-sensitivity testing is not practical at this time. However, by predicting recurrence months before current surveillance modalities, these models might provide a window of opportunity for increased surveillance and differentiation of treatment, especially in patients at higher risk of recurrent disease.

Our study had limitations. The patient population derives from a single referral center, which may result in variations relative to the general population. For instance, nearly a third of patients underwent neoadjuvant treatment. However, this was not associated with the rate of tumor engraftment; moreover, multivariable-adjusted survival models adjusted for different peri-operative treatment status, minimizing any potential biases. A small proportion (16%) of patients in our study had metastatic disease at the time of surgery, introducing heterogeneity in analyses of OS. To address this issue, we conducted a separate analysis of RFS among the more homogeneous subset of patients with resectable primary tumors and no evidence of metastatic disease.

In conclusion, successful establishment of PDAC PDX predicts an increased risk of disease recurrence and mortality in the original patients. Lymphovascular invasion and lymph node positivity might reflect an underlying biological mechanism that allows these tumors to establish and thrive in a new host environment. These models are able to faithfully reproduce the cancer and stromal architecture from the original tumor, and may therefore be valuable tools to test new therapeutic alternatives and identify patients who are at very high risk of disease recurrence following resection.

**Acknowledgments**

We would like to thank Yuto Suyama, Annika Reczek, and Kate Von Alt for their technical assistance.
Author Contributions

**Conceptualization:** Ilaria Pergolini, Vicente Morales-Oyarvide, Carlos Fernández-del Castillo, Andrew S. Liss.

**Data curation:** Ilaria Pergolini, Vicente Morales-Oyarvide, Andrew S. Liss.

**Formal analysis:** Ilaria Pergolini, Vicente Morales-Oyarvide, Mari Mino-Kenudson, Kim C. Honselmann, Cristina R. Ferrone, Keith D. Lillemoe, Nabeel Bardeesy, David P. Ryan, Sarah P. Thayer, Andrew L. Warshaw, Carlos Fernández-del Castillo, Andrew S. Liss.

**Funding acquisition:** Keith D. Lillemoe, David P. Ryan, Sarah P. Thayer, Andrew L. Warshaw, Carlos Fernández-del Castillo, Andrew S. Liss.

**Investigation:** Ilaria Pergolini, Vicente Morales-Oyarvide, Mari Mino-Kenudson, Kim C. Honselmann, Matthew W. Rosenbaum, Sabikun Nahar, Marina Kem, Andrew S. Liss.

**Methodology:** Ilaria Pergolini, Vicente Morales-Oyarvide, Mari Mino-Kenudson, Kim C. Honselmann, Sabikun Nahar, Marina Kem, Andrew S. Liss.

**Project administration:** Sarah P. Thayer, Andrew L. Warshaw, Carlos Fernández-del Castillo, Andrew S. Liss.

**Resources:** Mari Mino-Kenudson, Cristina R. Ferrone, Keith D. Lillemoe, Nabeel Bardeesy, Sarah P. Thayer, Andrew L. Warshaw, Carlos Fernández-del Castillo.

**Supervision:** Keith D. Lillemoe, Nabeel Bardeesy, David P. Ryan, Andrew L. Warshaw, Carlos Fernández-del Castillo, Andrew S. Liss.

**Validation:** Andrew S. Liss.

**Visualization:** Andrew S. Liss.

**Writing – original draft:** Ilaria Pergolini, Vicente Morales-Oyarvide, Andrew S. Liss.

**Writing – review & editing:** Ilaria Pergolini, Vicente Morales-Oyarvide, Mari Mino-Kenudson, Kim C. Honselmann, Matthew W. Rosenbaum, Sabikun Nahar, Marina Kem, Cristina R. Ferrone, Keith D. Lillemoe, Nabeel Bardeesy, David P. Ryan, Sarah P. Thayer, Andrew L. Warshaw, Carlos Fernández-del Castillo, Andrew S. Liss.

References

1. Siegel R, Miller K, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017; 67(1):7–30. https://doi.org/10.3322/caac.21387 PMID: 28055103

2. Bailey P, Chang DK, Nones K, Johns AL, Patch A-M, Gingras M-C, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016; 531(7592):47–52. https://doi.org/10.1038/nature16965 PMID: 26909576

3. Biankin A V., Waddell N, Kassahn KS, Gingras M-C, Muthuswamy LB, Johns AL, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012; 491(7424):399–405. https://doi.org/10.1038/nature11547 PMID: 23103869

4. Jones S, Zhang X, Parsons DW, Lin JC-H, Leary RJ, Angenendt P, et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science 2008; 321(5897):1801–6. https://doi.org/10.1126/science.1164368 PMID: 18772397

5. Ryan DP, Hong TS BN. Pancreatic adenocarcinoma. N Engl J Med. 2014; 371:2140–1.

6. Kadaba R, Birke H, Wang J, Hooper S, Andl CD, Di Maggio F, et al. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J Pathol. 2013; 230(1):107–17. https://doi.org/10.1002/path.4172 PMID: 23359139

7. Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S. Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas. 2004; 28(1):38–44. PMID: 14707728
8. Müerköster SS, Werbing V, Koch D, Sipos B, Ammerpohl O, Kalthoff H, et al. Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma—Epigenetic downregulation of caspases. Int J Cancer. 2008; 123(1):1751–60. https://doi.org/10.1002/ijc.23703 PMID: 18649362

9. Müerköster S, Wegehenkel K, Arlt A, Witt M, Sipos B, Kruse ML, et al. Tumor Stroma Interactions Induce Chemoresistance in Pancreatic Ductal Carcinoma Cells Involving Increased Secretion and Paracrine Effects of Nitric Oxide and Interleukin-1β. Cancer Res. 2004; 64(4):1331–7. PMID: 14973050

10. Hwang C-I, Boj SF, Clevers H, Tuveson DA. Pre-clinical Models of Pancreatic Ductal Adenocarcinoma. J Pathol 2016; 238(2):197–204. https://doi.org/10.1002/path.4651 PMID: 26419819

11. Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Mouse models of pancreatic cancer. World J Gastroenterol. 2012; 18(12):1286–94. https://doi.org/10.3748/wjg.v18.i12.1286 PMID: 22493542

12. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nat Protoc 2009; 4(11):1670–80. https://doi.org/10.1038/nprot.2009.171 PMID: 19876027

13. Rubio-Viqueira B, Jimeno A, Cusatis G, Zhang X, Iacobuzio-Donahue C, Karikari C, et al. An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res. 2006; 12(15):4652–61. https://doi.org/10.1158/1078-0432.CCR-06-0113 PMID: 16899615

14. Pérez-Torras S, Vidal-Pia A, Miquel R, Almendro V, Fernández-Cruz L, Navarro S, et al. Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening. Cell Oncol. 2011; 34(6):511–21.

15. Walters DM, Stokes JB, Adair SJ, Stelow EB, Borgman CA, Lowrey BT, et al. Clinical, Molecular and Genetic Validation of a Murine Orthotopic Xenograft Model of Pancreatic Adenocarcinoma Using Fresh Human Specimens. Ouellette MM, editor. PLoS One 2013; 8(10):e77065. https://doi.org/10.1371/journal.pone.0077065 PMID: 24204737

16. Jun E, Jung J, Jeong SY, Choi EK, Kim MB, Lee JS, et al. Surgical and oncological factors affecting the successful engraftment of patient-derived xenografts in pancreatic ductal adenocarcinoma. Anticancer Res. 2016; 36(2):517–22. PMID: 26851005

17. Garrido-Laguna I, Uson M, Rajeshkumar N V., Tan AC, De Oliveira E, Karikari C, et al. Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer. Clin Cancer Res. 2011; 17(17):5793–800. https://doi.org/10.1158/1078-0432.CCR-11-0341 PMID: 21742805

18. Thomas RM, Truty MJ, Kim M, Kang Y, Zhang R, Chatterjee D, et al. The Canary in the Coal Mine: The Growth of Patient-Derived Tumor grafts in Mice Predicts Clinical Recurrence after Surgical Resection of Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 2015; 22(6):1884–92. https://doi.org/10.1245/s10434-014-4241-1 PMID: 25404477

19. Delitto D, Pham K, Vlada AC, Sarosi GA, Thomas RM, Behms KE, et al. Patient-derived xenograft models for pancreatic adenocarcinoma demonstrate retention of tumor morphology through incorporation of murine stromal elements. Am J Pathol 2015; 185(5):1297–303. https://doi.org/10.1016/j.ajpath.2015.01.016 PMID: 25770474

20. Huang Y, Nahar S, Nakagawa A, Fernandez-Barrena MG, Mertz JA, Bryant BM, et al. Regulation of GLI underlies a role for BET bromodomains in pancreatic cancer growth and the tumor microenvironment. Clin Cancer Res. 2016; 22(6):4259–70. https://doi.org/10.1158/1078-0432.CCR-15-2068 PMID: 27169995

21. Días-Santagata D, Akhavanfard S, David SS, Vernovsky K, Carvalho J, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBO Mol Med. 2010; 2(5):146–58. https://doi.org/10.1002/emmm.201000070 PMID: 20432502

22. Sorio C, Bonora A, Orlandini S, Moore PS, Capelli P, Cristofori P, et al. Successful xenografting of cryopreserved primary pancreatic cancers. Virchows Arch. 2001; 438(2):154–8. PMID: 11253117

23. Linnebacher M, Maletzki C, Ostwald C, Klier U, Krohn M, Klar E, et al. Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer. 2010; 10:362. https://doi.org/10.1186/1471-2407-10-362 PMID: 20615215

24. Lim KH, Chung E, Khan A, Cao D, Linehan D, Ben-Josef E W-GA. Neoadjuvant therapy of pancreatic cancer: the emerging paradigm? Oncologist. 2012; 17: 182–200. https://doi.org/10.1634/theoncologist.2011-0268 PMID: 22250057

25. Ying H, Dey P, Yao W, Kimmelman AC, Draetta GF, Maitra A, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 2016 Feb; 30(4):355–85. https://doi.org/10.1101/gad.275776.115 PMID: 26883357

26. Duda DG, Fukumura D, Munn LL, Booth MF, Brown EB, Huang P, et al. Differential transplantability of tumor-associated stromal cells. Cancer Res. 2004 Sep; 64(17):5920–4. https://doi.org/10.1158/0008-5472.CAN-04-1268 PMID: 15342367
27. Hidalgo M, Amant F, Biankin A V., Budinská E, Byrne AT, Caldas C, et al. Patient-derived Xenograft models: An emerging platform for translational cancer research. Cancer Discov. 2014; 4(9):998–1013. https://doi.org/10.1158/2159-8290.CD-14-0001 PMID: 25185190

28. Mattie M, Christensen A, Chang MS, Yeh W, Said S, Shostak Y, et al. Molecular Characterization of Patient-Derived Human Pancreatic Tumor Xenograft Models for Preclinical and Translational Development of Cancer Therapeutics 1,2. Neoplasia. 2013; 15:1138–1150, IN10–IN17. PMID: 24204193

29. Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res 2011; 1 (4):482–97. PMID: 21984967

30. Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017 Feb; jem.20162024.

31. Oh BY, Lee WY, Jung S, Hong HK, Nam D- H, Park YA, et al. Correlation between tumor engraftment in patient-derived xenograft models and clinical outcomes in colorectal cancer patients. Oncotarget. Impact Journals; 2015 Jun; 6(18):16059–68.

32. John T, Kohler D, Pintilie M, Yanagawa N, Pham N- A, Li M, et al. The Ability to Form Primary Tumor Xenografts Is Predictive of Increased Risk of Disease Recurrence in Early-Stage Non-Small Cell Lung Cancer. Clin Cancer Res. 2011 Jan; 17(1):134–41. https://doi.org/10.1158/1078-0432.CCR-10-2224 PMID: 21081655

33. Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, et al. DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer. J Clin Oncol. 2009 Apr; 27(11):1806–13. https://doi.org/10.1200/JCO.2008.17.7188 PMID: 19273710